Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
Ana-Alicia Beltran-Bless(University of Ottawa), Christina M. Canil(University of Ottawa), Simon Tanguay(McGill University Health Centre), Naveen S. Basappa, Rodney H. Breau(University of Ottawa), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Noa Shani Shrem(Ottawa Hospital), Frédéric Pouliot(Université Laval), Bimal Bhindi, Nazanin Fallah‐Rad(Princess Margaret Cancer Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Antonio Finelli(University Health Network), Jeffrey Graham(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Camilla Tajzler
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
|The Journal of Urology|2020|268